statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In a preclinical model of pulmonary fibrosis, a Surrozen antibody-based SWAP platform molecule decreased pulmonary inflammation and fibrosis and improved lung function Surrozen Wnt mimetic SWAP...

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen announces up to $192.5M private placement of securities priced at-the-market under Nasdaq rules...

Surrozen announces up to $192.5M private placement of securities priced at-the-market under Nasdaq rules

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Surrozen announces up to $192.5M private placement

Surrozen announces safety, pharmacodynamic, liver function data for SZN-043

- $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of warrants- Initial capital funds expansion of Phase 1b trial in severe alcohol-associated...

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

-Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events-Phase 1a data demonstrated target engagement, a pharmacodynamic effect and effects on liver...

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 3,400 shares, a growth of 25.9...

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Update

Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...

Surrozen Provides Corporate Update on Clinical Programs

Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Watchers	1,196
52-Wk Low	$4.50
52-Wk High	$16.19

Volume	1,233.00
52-Wk High	$16.19
52-Wk Low	$4.50

Period	Estimated	Reported	Surprise	Result
Q1'24	-$4.25	-$4.24	0.24%	BEAT
Q4'23	-$3.00	--	--	N/A
Q3'23	-$4.43	-$5.10	-15.25%	MISSED
Q2'23	-$6.15	-$4.65	24.39%	BEAT
Q1'23	-$5.25	-$7.20	-37.14%	MISSED

SRZN Surrozen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals